Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: Angela M. DeMichele, Stacy Moulder, Meredith Buxton, Douglas Yee, Anne Wallace, Jo Chien, Claudine Isaacs, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Julie Lang, Henry Kaplan, Susan Minton, Andres Forero, Anthony Elias, Rita Nanda, Larissa Korde, Richard Schwab, Michelle Melisko, Ashish Sanil, Michael Hogarth, Nola Hylton, Melissa Paoloni, Fraser Symmans, Jane Perlmutter, Julia Lyandres, Christina Yau, Don Berry, Laura Esserman, I-SPY 2 TRIAL Investigators
Institutions: University of Pennsylvania, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, University of Minnesota, University of California San Diego, Georgetown University, Loyola University Medical Center, Loyola Medicine, Mayo Clinic, Oregon Health & Science University, The University of Texas Southwestern Medical Center, University of Southern California, Swedish Medical Center, Moffitt Cancer Center, University of Alabama at Birmingham, University of Colorado Denver, University of Chicago, University of Washington, Berry Consultants, LLC (United States), University of California, Davis, Patient-Centered Outcomes Research Institute
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2476617398